NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit

REGENERON PHARMACEUTICALS, INC., Plaintiff-Appellant

 $\mathbf{v}.$

MYLAN PHARMACEUTICALS INC., BIOCON BIOLOGICS INC.,

 $Defendants ext{-}Cross ext{-}Appellants$

AMGEN USA, INC., Defendant

2024-1402, 2024-1405

Appeals from the United States District Court for the Northern District of West Virginia in No. 1:22-cv-00061-TSK-JPM, Chief Judge Thomas S. Kleeh.

Before Chen, Linn, and Hughes, $\mathit{Circuit\ Judges}$. Per Curiam.

ORDER

Following this court's February 22, 2024 show cause order, the parties agree that the court lacks jurisdiction over both the appeal and cross-appeal from the district court's December 27, 2023 decision resolving fewer than all

2 REGENERON PHARMACEUTICALS, INC. v. MYLAN PHARMACEUTICALS INC.

claims at issue. Under the circumstances, we agree and conclude that dismissal is appropriate.

Accordingly,

IT IS ORDERED THAT:

- (1) Appeal Nos. 2024-1402 and 2024-1405 are dismissed.
 - (2) Each party shall bear its own costs.

FOR THE COURT

de APPEALS FOR

Jarrett B. Perlow Clerk of Court

April 12, 2024 Date

ISSUED AS A MANDATE: April 12, 2024